Histone Deacetylase Inhibitors May Be a Way to Treat Fatty Liver Disease in Cushing’s Patients, Study Finds
Therapies known as histone deacetylase inhibitors reduced fatty liver disease in a rat model of Cushing’s syndrome, a study reports. (HDACi) was found to reduce hepatic steatosis – also known as fatty liver disease – in a rat model of Cushing’s syndrome, according to a new study. Researchers’ article, “Histone…